Skip to main content

Table 1 Comparison of the studies on the use of Tocilizumab treatment in FMF patients

From: Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

 

Fujikawa et al. (2013) [33]

Serelis et al. (2015) [34]

Hamanoue et al. (2015) [18]

Yilmaz et al. (2015) [19]

Umeda et al. (2015) [35]

Our cases

Total number of patients

1

1

1

11

1

12

Adult/children

1/0

1/0

1/0

11/0

1/0

12/0

Duration of Tocilizumab treatment, mean (months)

Not specified

48

41

57

9

18

Gene analysis

 M694V/M694V

   

7

 

4

 M694V/M680I

   

2

 

1

 M694I/- heterozygous

1

     

 Other

 

Not specified

1

2

1

7

Indications for Tocilizumab treatment

 Amyloidosis

 

1

1

11

 

12

 Frequent attacks (fever, serositis)

1

1

1

 

1

 

 Arthritis/spondylitis

 

1

1

   

 Protracted myalgia

    

1

 

 Henoch-Schonlein purpura

      

 Colchicine intolerance/side effect

      

Effect of Tocilizumab during follow up

 No attacks

1

 

Unknown

8

1

10

 Decrease number of attacks

 

1

   

1

 No response

     

1

 Proteinuria in patients with amyloidosis

 

decreased

decreased

Decreased in 7

 

9

Side effects

None

Unknown

Unknown

Elevation of liver enzymes, mild thrombocytopenia

Not specified

Transient diplopia, deterioration in hypertension